Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

Summary

The goal of this clinical research study is to find the highest tolerable dose of TPI 287 that can be given to patients with metastatic melanoma. Researchers want to find out if TPI 287 can control the disease. The safety of TPI 287 will also be studied.

Timeline

Start

2013-09

Primary completion

2016-09

Completion

—

Drugs

Indications